Overview

Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Status:
Completed

Trial end date:
2003-12-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate whether Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution is an effective and safe treatment in patients with chronic idiopathic thrombocytopenic purpura.

Phase:

Phase 2

Details

Lead Sponsor:

Baxalta now part of Shire
Baxalta US Inc.

Treatments:

Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Pharmaceutical Solutions
Rho(D) Immune Globulin